Mati Therapeutics announced that its international patent portfolio now comprises 100 issued patents. Included in the portfolio is recently granted U.S. Patent No. 9,610,271 titled “Sustained release delivery of active agents to treat glaucoma and ocular hypertension." The patent, which expires in 2033, contains subject matter related to a method for decreasing ocular pressure by implanting a lacrimal implant into one or both puncta (tear ducts) of the eye.
This newly issued patent further enhances Mati’s patent portfolio, which consists of 100 issued patents and numerous patent applications to which Mati has exclusive rights in the U.S. and other major international markets. The patents cover 17 patent families, including important elements of Mati's Evolute punctal plug delivery system for treatment of ocular indications. The Evolute platform includes features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution and sustained release formulations currently in development for the treatment of post-operative pain and inflammation. The proprietary technology has the potential to be used for multiple disease states with consistent, sustained efficacy.
“The granting of 100 patents is a significant milestone for any company, but a very meaningful milestone for a small private company such as Mati. Our unique platform technology is under development for a number of indications including postoperative inflammation and pain, glaucoma and ocular hypertension, ocular allergy, and dry eye,” Bob Butchofsky, CEO of Mati, said in the news release. “Since its inception over 4 years ago, Mati has focused on innovation, and continues to build a significant intellectual property portfolio for sustained drug delivery platform covering the U.S., Europe, Canada, Japan, and China. We believe our patent portfolio provides Mati with a competitive advantage in research and development that will remain in place for many years to come.”